DOCSLIB.ORG

50 Years of R&D Innovation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
50 Years of R&D Innovation GSK – 50 years of R&D innovation Medicines Seretide/ Ventolin Augmentin Retrovir Advair Votrient Tivicay Triumeq Asthma Bacterial infections HIV/AIDS Asthma (COPD) Renal cell carcinoma HIV/AIDS HIV/AIDS 1969 1981 1987 1998 (2003) 2010 2013 2014 Amoxil Zantac Seroxat/Paxil Trizivir Relvar/ Anoro Ellipta Mekinist Bacterial infections Stomach ulcers Depression, various HIV/AIDS Breo Ellipta COPD BRAF V600+ 1972 1981 anxiety disorders 2000 COPD and asthma 2014 metastatic melanoma 1991 2013 2014 Vaccines Boostrix Infanrix hexa Fluarix/ Diphtheria, tetanus, Diphtheria, tetanus, pertussis, Cervarix Priorix-Tetra pertussis. Booster Haemophilus influenzae type B, Human papilloma Measles, mumps, rubella, FluLaval Tetra Priorix Havrix Seasonal flu Measles, mumps, rubella Hepatitis A vaccination polio and hepatitis B virus type 16 and 18 varicella (chickenpox) 2012 (quadrivalent, 4 strains) 1970 1992 1994 2000 2007 2013 Engerix B Fluarix/FluLaval Twinrix Rotarix Synflorix Nimenrix Hepatitis B Seasonal flu (3 strains) Hepatitis A and B Rotavirus Invasive pneumococcal Meningitis ACWY 1986 1992 1996 2005 disease, pneumonia 2012 acute otitis media 2009 Consumer Healthcare products Sensodyne Sensodyne Panadol Actifast Panadol Advance Repair & Protect Zovirax Duo Oral health Pain relief Pain relief Oral health Skin health 1961 2001 2008 2011 2014 Aquafresh Triple Action Sensodyne Women’s Fenbid Chewable Flonase/Flixonase Oral health Pronamel Horlicks Pain relief Allergic rhinitis 1981 Oral health Health drink 2014 2015 2006 2008 1961 2015 Not all products are still owned, produced or marketed by GSK. Excludes products now owned by GSK through the recent transaction with Novartis. GSK – 50 years of R&D innovation Medicines Product name Generic name Indication Date of Product name Generic name Indication Date of first launch first launch Ventolin salbutamol sulphate Asthma 1969 Seretide/Advair salmeterol xinafoate and COPD 2003 fluticasone propionate Amoxil amoxicillin Bacterial infections 1972 Hycamtin topotecan Small cell lung cancer 2007 Becotide/ beclomethasone Asthma 1972 Beclovent dipropionate Tykerb/Tyverb lapatanib Advanced and metastatic breast 2007 cancer in HER2 positive patients Beconase beclomethasone Allergic rhinitis 1975 dipropionate Avamys/Veramyst fluticasone furoate Allergic rhinitis 2008 Tagamet cimetidine Stomach ulcers 1976 Votrient pazopanib Renal cell carcinoma 2009 Augmentin co-amoxiclav Bacterial infections 1981 Benlysta belimumab Systemic lupus erythematosus 2011 Zovirax aciclovir Herpes infections 1981 Votrient pazopanib Soft tissue sarcoma metastatic 2013 Zantac ranitidine hydrochloride Stomach ulcers 1981 Relvar/Breo fluticasone furoate and Asthma and COPD 2013 Ellipta vilanterol terfenatate Wellbutrin bupropion Depression 1982 Tivicay dolutegravir HIV/AIDS 2013 Retrovir zidovudine HIV/AIDS 1987 Anoro Ellipta umeclidinium bromide and COPD 2014 Imigran sumatriptan Migraine 1990 vilanterol terfenatate Serevent salmeterol xinafoate Asthma 1990 Incruse Ellipta umeclidinium bromide COPD 2014 Seroxat/Paxil paroxetine Depression, various anxiety disorders 1991 Arnuity Ellipta fluticasone furoate Asthma 2014 Zofran ondansetron hydrochloride Post operative or chemotherapy 1991 Triumeq abacavir, dolutegravir, HIV/AIDS 2014 induced nausea lamivudine Lamictal lamotrigine Epilepsy, bipolar disorder 1990 Mekinist trametinib BRAF V600+ metastatic melanoma 2014 Requip ropinirole Parkinson’s disease 1996 Tafinlar dabrafenib BRAF V600+ metastatic melanoma 2014 Seretide/Advair salmeterol xinafoate and Asthma 1998 fluticasone propionate Avandia rosiglitazone Type 2 diabetes 1999 Trizivir abacavir, lamivudine, HIV/AIDS 2000 zidovudine Avodart dutasteride Benign prostatic hyperplasia 2001 Kivexa abacavir, lamivudine HIV/AIDS 2004 Not all products are still owned, produced or marketed by GSK. Excludes products now owned by GSK through the recent transaction with Novartis. GSK – 50 years of R&D innovation Vaccines Product name Indication Date of Product name Indication Date of first launch first launch Poliorix Polio 1956 Synflorix Invasive pneumococcal disease, pneumonia acute 2009 otitis media Cendevax Rubella 1969 Arepanrix Pandemic flu (H1N1) 2010 Priorix Measles, mumps, rubella 1970 MenHibrix Meningitis C, Y and Haemophilus influenzae type B 2012 Varilrix Varicella (chickenpox) 1984 Priorix Tetra Measles, mumps, rubella, varicella (chickenpox) 2012 Engerix B Hepatitis B 1986 Nimenrix Meningitis ACWY 2012 Havrix Hepatitis A 1992 Fluarix/FluLaval Tetra Seasonal flu (quadrivalent, 4 strains) 2013 Fluarix/FluLaval Seasonal flu (trivalent, 3 strains) 1992 Boostrix Diphtheria, tetanus, pertussis. Booster vaccination 1994 Twinrix Hepatitis A and B 1996 Tritanrix HepB/Hib Diphtheria, tetanus, pertussis, hepatitis B, with and 1996 without Haemophilus influenzae type B Infanrix Hib Diphtheria, tetanus, pertussis, Haemophilus influenzae 1997 type B Infanrix Polio Diphtheria, tetanus, pertussis, polio 1997 Typherix Typhoid fever 1998 Hepatyrix Hepatitis A and typhoid fever 1999 Infanrix hexa Diphtheria, tetanus, pertussis, Haemophilus influenzae 2000 type B, polio and hepatitis B Mencevax Meningitis ACW 2003 Rotarix Rotavirus 2005 Fendrix Hepatitis B 2005 Menitorix Meningitis C and Haemophilus influenzae type B 2006 Cervarix Human papilloma virus type 16 and 18 2007 Pandemrix/Pre-pandemrix Pandemic flu (H5N1) 2008 Not all products are still owned, produced or marketed by GSK. Excludes products now owned by GSK through the recent transaction with Novartis. GSK – 50 years of R&D innovation Consumer Healthcare products Product name Indication / use Date of Product name Indication / use Date of first launch first launch Sensodyne Oral health 1961 Fenbid Chewable Pain relief 2014 Aquafresh Oral health 1973 Zovirax Duo Skin health 2014 Aquafresh Triple Action Oral health 1981 Sensodyne Mouthwash Oral health 2015 Aquafresh Kids Oral Health 1985 Flonase/Flixonase Allergic rhinitis 2015 Poligrip Ultra Hold Oral health 1990 Nicorette Smokers health 1996 NicoDerm CQ SmartControl Technology Smokers health 1997 NiQuitin Clear Patch Aquafresh Flex Toothbrush Oral health 1998 Physiogel BioMimic Technology Skin health 2000 Panadol Actifast Pain relief 2001 Abbreva Skin health 2002 Sensodyne Pronamel Oral health 2006 Panadol Extended Release Pain relief 2006 Panadol Advance Optizorb Technology Pain relief 2008 Women’s Horlicks Micronutrients for women Health drink 2008 Sensodyne Repair & Protect With Novamin Oral health 2011 Panadol Extra Optizorb Technology Pain relief 2011 NiQuitin Strips Smokers health 2013 Aquafresh Complete Care Oral health 2013 Mouthwash Aquafresh Complete Care Oral health 2014 Sensodyne True White True White Technology Oral health 2014 Not all products are still owned, produced or marketed by GSK. Excludes products now owned by GSK through the recent transaction with Novartis..
Load more

Recommended publications
  • The Everyday Lives of Recovering Heroin Users
    The everyday lives of recovering heroin users Joanne Neale Sarah Nettleton Lucy Pickering The everyday lives of recovering heroin users The everyday lives of recovering heroin users Joanne Neale Sarah Nettleton Lucy Pickering Joanne Neale Professor of Public Health Faculty of Health & Life Sciences Oxford Brookes University Jack Straw’s Lane Marston Oxford OX3 0FL Email: [email protected] Sarah Nettleton Reader in Sociology Department of Sociology Wentworth College University of York Heslington York YO10 5DD Email: [email protected] Lucy Pickering Lecturer in Anthropology School of Social and Political Sciences University of Glasgow Adam Smith Building Glasgow G12 8RT Email: [email protected] Published by the RSA 8 John Adam Street London WC2N 6EZ +44 (0)20 7930 5115 Registered as a charity in England and Wales no. 212424 and in Scotland no. SCO 37784 Copyright © Joanne Neale 2012 The RSA is an enlightenment organisation devoted to finding innovative and practical solutions to today’s pressing social problems Cover photo: ‘Wings of butterfly,’ John Foxx. © Thinkstock Designed by Soapbox, www.soapbox.co.uk Printed and bound by CPI Antony Rowe www.theRSA.org Contents Acknowledgements 9 Foreword 10 Chapter 1: Setting the scene 14 Why read this book? 14 Why focus on recovery? 15 What is recovery? 15 A study of the everyday lives of recovering heroin users 17 Structure of the book 18 Chapter 2: Considering recovery 20 Introduction 20 Mapping services and support 20 Factors that can encourage and sustain recovery efforts
    [Show full text]
  • Cross Reaction Guide
    Individual Reaction Key Methadone(MTD) Phencyclidine(PCP) Amphetamines(AMP) Tricyclic Antidepressants(TCA) Oxycodone(OXY) Barbiturates(BAR) Methamphetamines(MET) Benzodiazepines(BZO) Tramadol(TML) Opiates(OPI, MOP, MOR) Marijuana(THC) Ecstasy(MDMA) Cotinine(COT) Cocaine(COC) Buprenorphine(BUP) Propoxyphene(PPX) Non-reactive Multiple Reaction Key MET and AMP OPI and OXY MDMA and MET MDMA and AMP MET and TCA Generic Name of Compound Trade Name of Compound Results 6-Acetylmorphine N/A Positive: Opiates(OPI, MOP, MOR) Aceta, Acephen, Apacet, Dapacen, Feverall, Acetaminophen (aka Paracetamol) Tylenol, Excedrin (combination), Panadol, Non-reactive Tempra Acetaminophen with Codeine (aka Positive: Opiates(OPI, MOP, MOR) Tylenol 3, Tylenol with Codeine Paracetamol with Codeine) Potential reactants: Dihydrocodeine Acetophenetidin Phenacetin Non-reactive Aspirin, Anadin, Anasin, Bufferin, Caprin, Acetylsalicyclic Acid Disprin, Ecotrin, Empirin, Excedrin Non-reactive (combination) Allobarbital N/A Positive: Barbiturates(BAR) Alphenol N/A Positive: Barbiturates(BAR) Positive: Benzodiazepines(BZO) Potential Alprazolam Xanax reactants: Oxaprozin (Daypro), Sertraline Aluminum Chloride Hexahydrate Drichlor, Anhydrol Forte Non-reactive Alu-Cap, Alisone, Gastrocote, Kolanticon, Aluminum Hydroxide Non-reactive Maalox TC, Mucogel, Pyrogastrone, Topal Alverine Citrate Spasmonal, Spasmonal Fibre Non-reactive Amantadine Symmetrel Positive: Amphetamines(AMP) SpearesMedical.comAminopyrine N/A Non-reactive Elavil, Lentizol, Tryptizol, Triptafen, Triptafen- Amitriptyline
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • With Nicotine Replacement Therapies in Smoking Cessation Vol
    Health Technology Assessment Health Technology Health Technology Assessment 2008; Vol. 12: No. 2 2008; 12: No. 2 Vol. ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis D Wang, M Connock, P Barton, A Fry-Smith, P Aveyard and D Moore Feedback The HTA Programme and the authors would like to know your views about this report. The Correspondence Page on the HTA website (http://www.hta.ac.uk) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website. We look forward to hearing from you. February 2008 The National Coordinating Centre for Health Technology Assessment, Mailpoint 728, Boldrewood, Health Technology Assessment University of Southampton, NHS R&D HTA Programme Southampton, SO16 7PX, UK. HTA Fax: +44 (0) 23 8059 5639 Email: [email protected] www.hta.ac.uk http://www.hta.ac.uk ISSN 1366-5278 HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents. Non-UK purchasers will have to pay a small fee for post and packing.
    [Show full text]
  • PDF (Irish Pharmacist January 2020)
    EXCLUSIVE COVERAGE FROM THE RECENT IRISH MEDICATION SAFETY NETWORK ANNUAL CONFERENCE ABOUT-TURN WE LOOK AT WHAT MIGHT BE NEXT FOR PHARMACISTS FOLLOWING THE REVERSAL IN PROPOSED FEE CUTS DUMB AND DUMBER? ARE PHARMACISTS A LITTLE LACKING IN GREY MATTER WHEN IT COMES TO PRICING, ASKS FINTAN MOORE PLUS CLINICAL CONTENT: ASTHMA ❋ COPD ❋ EYE CARE ❋ SMOKING CESSATION TENDER CARE AT Every Change For topical use only. Cleanse and dry the affected area before applying. A copy of the summary of product characteristics is available upon request. The active ingredient in Caldesene Medicated Powder is Calcium Undecylenate 10% w/w, 20g, 55g, 100g pack size. For supply through general sale. PA 126/152/1 PA Holder: Clonmel Healthcare Ltd., Waterford Road, Clonmel, Co. Tipperary. Date Prepared: October 2019. 2019/ADV/CAL/150H NEW TREATS HEARTBURN AND ACID REFLUX. ONE TABLET PER DAY. LASTS 24 HOURS. AVAILABLE IN PACKS OF 7s AND 14s. Marketed by CCF:22656 Date of preparation: (10-19) ABBREVIATED PRESCRIBING INFORMATION Product Name: Emazole Control 20 mg Gastro-Resistant Tablets Composition: Each tablet contains 20 mg esomeprazole (as magnesium dihydrate). Description: Light pink oval film coated tablet. Indication(s): Proton Pump Inhibitor (PPI): Short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Dosage: Swallow tablets whole with liquid, do not chew or crush. Disperse in half a glass of non-carbonated water if difficulty in swallowing. Stir until tablets disintegrate, drink liquid with pellets immediately or within 15 min, or administer through a gastric tube. Do not chew or crush pellets. Adults: The recommended dose is 20 mg esomeprazole (one tablet) per day.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • Paul M Mahan Matthews
    17 April 2015 PAUL McMAHAN MATTHEWS [email protected] PRIMARY APPOINTMENTS July, 2014- Edmond and Lily Safra Professor of Translational Neuroscience and Therapeutics, Division of Brain Sciences, Department of Medicine, Imperial College London Secured endowment for, and first holder of, new Chair associated with the Divisional Head and posts (Edmond and Lily Safra Scholars) accompanying its foundation. April, 2012- Professor and Head, Division of Brain Sciences, Department of Medicine, Imperial College London Leading a new integration of over 70 academics all clinical and basic neurosciences, neuropsychopharmacology, neurology and mental health within a Division of 200 staff in the Faculty of Medicine with senior management responsibilities across the three academic hospital sites of Imperial College, London. Additional responsibilities as Deputy Director (2008- ) of the Wellcome Trust- GSK Translational Medicine Training Programme, Deputy Director (2011- ) of the BRC Institute for Translational Medicine and Therapeutics, Biomedical Research Centre (BRC) Theme Lead for Neuroscience, co-Director of the Neurotechnology Network and the EPSRC Centre for Doctoral Training in Neurology and Research Advisory Board for the Data Science Institute. July, 2012- February 2014 Vice-President for Integrative Medicines Development, Neurosciences and Medicine Development Lead, GlaxoSmithKline (joint appointment with Imperial College) Leading late phase development programme. Senior advisor to the Head of Neurosciences and China R and D with specific
    [Show full text]
  • Formulation of Novel Buccal Mucosal Drug Delivery Systems for Nicotine Replacement Therapy (Nrt)
    FORMULATION OF NOVEL BUCCAL MUCOSAL DRUG DELIVERY SYSTEMS FOR NICOTINE REPLACEMENT THERAPY (NRT). OBINNA CHIKWADO OKEKE A thesis submitted in partial fulfilment of the requirements of the University of Greenwich for the Degree of Doctor of Philosophy January 2017 DECLARATION “I certify that this work has not been accepted in substance for any degree, and is not concurrently being submitted for any purpose. I also declare that this work is the result of my own investigations except where otherwise identified by references and that I have not plagiarised another’s work”. Mr. Obinna C. Okeke (Candidate) Dr J.S. Boateng (First supervisor) i ACKNOWLEDGEMENTS I would like to express my sincere gratitude to my supervisor, Dr Joshua Boateng, for his enormous support, encouragement and general guidance throughout my research. His constant support and encouragement has led me to believe in myself and give out my best. I also appreciate the University of Greenwich for providing the facilities and student support within this period. I would like to acknowledge Dr Ian Slipper for all SEM and XRPD techniques as well as Devyani Amin for HPLC analysis. Thanks to all University staff for supporting my program. I also want to extend my deepest gratitude to my family. Their support and encouragement have led me to the person I am today. I am grateful to Dr Sam and Samantha Owusu-Ware and family for their support. Finally, to all my roommates, officemates, library IT and assistance team, project students under my supervision and fellow postgraduate students, I want to say I big thank you for your support.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Today's Research Tomorrow's Cure
    2018 Heart Research Institute Annual Review Accelerating Research Tomorrow’s cure Tomorrow’s Today’s research Today’s 2018 Heart Research Institute Annual Review Hello Future Accelerating 2018 Heart Research Institute Annual Review Research ACCELERATING Discoveries into therapies Knowledge into prevention Breakthroughs into cures Students into leaders Collaborations into partnerships 4 2018 Heart Research Institute Annual Review Inspiring Leaders 2018 Heart Research Institute Annual Review CONTENTS 06 HRI in 2018 08 Chairman’s Report 2018 10 Director of Cardiovascular Research Report 12 2018 Research and Media Highlights 16 Applied Materials Group 18 Atherosclerosis and Vascular Remodelling Group 20 Cardiac Imaging Group 22 Cardiometabolic Disease Group 24 Cardiovascular Medical Devices Group 26 Cell Therapeutics Group 28 Clinical Research Group 30 Haematology Research Group 32 Heart Rhythm and Stroke Prevention Group 34 High Blood Pressure Group 36 Thrombosis Group 38 Vascular Complications Group 40 Vascular Immunology Group 42 Inflammation and Fibrosis Research 44 PhD Students 45 Select Prizes and Awards 46 Select Conferences and Presentations 50 Select Publications 56 Board of Governors 59 International Board of Governors 60 Members of the Institute 62 Fundraising Report 66 Operations Report 6 2018 Heart Research Institute Annual Review The mission of the Heart Research Institute (HRI) is to prevent death and suffering from cardiovascular disease through an understanding of the biological processes that cause atherosclerosis and thrombosis, the major underlying causes of most heart attacks and strokes. 20 18 SHORT TERM LONG TERM The major short-term focus of our research There are four long-term objectives is to understand the development and for our research: progression of atherothrombotic conditions • To investigate mechanisms in which the arteries are narrowed and contributing to the pathogenesis restricted due to a build-up of fatty of cardiovascular disease.
    [Show full text]
  • Building Innovation, Performance and Trust
    Building Innovation, Performance and Trust Emma Walmsley, CEO Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate.
    [Show full text]
  • 2009 Nhamcs Micro-Data File Documentation Page 1
    2009 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the public use micro-data files of the 2009 National Hospital Ambulatory Medical Care Survey (NHAMCS). NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Surveys, which measure health care utilization across a variety of health care providers. There are two micro-data files produced from NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION SUMMARY OF CHANGES FOR 2009 The 2009 NHAMCS Emergency Department and Outpatient Department public use micro-data files are, for the most part, similar to the 2008 files, but there are some important changes. These are described in more detail below and reflect changes to the survey instrument, the Patient Record form. Emergency Departments 1. New or Modified Items a. In item 1, Patient Information, there is a new checkbox item “Arrival by Ambulance.” This replaces the 2008 item, “Mode of Arrival.” b.
    [Show full text]